Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.4%

2 terminated out of 27 trials

Success Rate

89.5%

+3.0% vs benchmark

Late-Stage Pipeline

19%

5 trials in Phase 3/4

Results Transparency

24%

4 of 17 completed with results

Key Signals

4 with results89% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (8)
P 1 (3)
P 2 (3)
P 3 (3)
P 4 (2)

Trial Status

Completed17
Unknown4
Recruiting3
Terminated2
Not Yet Recruiting1

Trial Success Rate

89.5%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT07553754Recruiting

Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis

NCT02426697Phase 3CompletedPrimary

Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy

NCT06884332Not ApplicableRecruitingPrimary

Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality

NCT07100444Completed

Spinal Metastasis as the First Presentation of Lung Malignancy: Clinical Characteristics and Postoperative Survival

NCT06903585Phase 2Not Yet Recruiting

Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy

NCT06806462Not ApplicableRecruitingPrimary

Biomolecular Markers of Bone Metastasis

NCT04592887Not ApplicableCompletedPrimary

Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases

NCT01833806Not ApplicableCompletedPrimary

A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT02609828Phase 3CompletedPrimary

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

NCT02999152Not ApplicableTerminatedPrimary

Validation of Radio-induced Damage Biomarkers

NCT02774213CompletedPrimary

A Study to Collect Data About Analgesia in Patients With Bone Metastasis

NCT02480634Phase 4Unknown

Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer

NCT02293642CompletedPrimary

Bone Pain Score Validation Initiative

NCT01998607Completed

Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw

NCT01586273Not ApplicableTerminatedPrimary

Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases

NCT02784652Phase 2CompletedPrimary

Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors

NCT00334139Phase 4Completed

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

NCT02705157UnknownPrimary

The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones

NCT02876991Not ApplicableUnknownPrimary

Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma

NCT02876731Not ApplicableCompleted

Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS)

Scroll to load more

Research Network

Activity Timeline